FULLTEXT DEL 1 AV 1
Kvartalsrapport Q3 2025
===== SIDA 1 ===== Interim report First quarter May–July 2025/26 Improved cash flow and solid performance in Europe First quarter • In constant exchange rates, net sales increased by 3 percent driven by Europe. Reported sales in SEK decreased by 5 percent amounting to SEK 3,646 M (3,825). • Book-to-bill ratio of 1.05 (1.10) supported by continued strong order growth for Elekta Evo. • Lower adjusted gross margin of 37.0 percent (37.8) due to changes in FX and tariff costs with a total impact of 190 basis points. • Adjusted EBIT amounted to SEK 235 M (283), corresponding to a margin of 6.5 percent (7.4). • Net income was SEK 106 M (71) and earnings per share before and after dilution was SEK 0.28 (0.18). • Cash flow after continuous investments improved by SEK 529 M YoY amounting to SEK -361 M (-891). 1 Compared to last fiscal year based on constant exchange rates. 2 Compared to last fiscal year May 2024 – Apr 2025 based on constant exchange rates. 3 Adjusted gross margin = Gross margin excluding items affecting comparability, see page 28. 4 Adjusted EBITDA = EBITDA excluding items affecting comparability, see page 28. 5 Adjusted EBIT = Operating income (EBIT) excluding items affecting comparability including the R&D impairment cost, see page 29. 6 Adjusted earnings per share = Net income excluding items affecting comparability, attributable to Parent Company shareholders, in relation to the weighted average number of shares (excluding treasury shares), see page 30. Group Summary SEK M 2025/26 2024/25 Δ RTM 2024/25 Δ Book-to-bill 1.05 1.10 -4% 1.09 1.09 -1% Net sales 3,646 3,825 -5% 17,838 18,016 -1% Net sales in constant exchange rates 3% 1 2% 2 Adjusted gross margin 3 37.0% 37.8% -0,8 ppts 37.6% 37.8% -0,2 ppts Adjusted EBITDA 4 548 600 -9% 3,345 3,396 -2% Adjusted EBITDA margin 4 15.0% 15.7% -0,7 ppts 18.8% 18.8% -0,1 ppts Adjusted EBIT 5 235 283 -17% 2,049 2,097 -2% Adjusted EBIT margin 5 6.5% 7.4% -0,9 ppts 11.5% 11.6% -0,2 ppts Gross margin 36.8% 37.0% -0,2 ppts 37.4% 37.4% 0 ppts EBITDA 532 522 2% 3,293 3,283 0% EBITDA margin 14.6% 13.6% 0,9 ppts 18.5% 18.2% 0,2 ppts EBIT 219 174 26% 935 890 5% EBIT margin 6.0% 4.5% 1,5 ppts 5.2% 4.9% 0,3 ppts Net income 106 71 50% 276 240 15% Cash flow after continuous investments -361 -891 529 1,586 1,056 529 Adjusted earnings per share before/after dilution, SEK 6 0.31 / 0.31 0.41 / 0.41 -23% 2.99 / 2.99 3.08 / 3.08 -3% Earnings per share before/after dilution, SEK 0.28 / 0.28 0.18 / 0.18 52% 0.71 / 0.71 0.62 / 0.62 15% 12 monthsQ1 ===== SIDA 2 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 2 Net sales at constant exchange rates grew by 3 percent primarily driven by strong performance in Europe. Operating cash flow after continuous investments improved by SEK 529 million, reaching SEK -361 million in the first quarter. First quarter summary Despite a slight decline in orders during the first quarter, our book-to-bill ratio remains above 1, reflecting a healthy business environment. Net sales at constant exchange rates grew by 3 percent, primarily driven by strong performance in Europe, where our latest linear accelerator, Elekta Evo, and our new software suite, Elekta ONE, are gaining traction as online adaptive treatment capabilities continue to set new benchmarks in the market. The adjusted gross margin in Q1 was impacted by normal seasonality and continued negative FX effects, resulting in a year-over-year decrease to 37.0 percent (37.8). In addition, this quarter had a negative impact from tariffs of SEK 33 M, which weighed on the margin performance by 90 bps. The negative impact was partly offset by price improvements. Adjusted EBIT margin for the first quarter came in at 6.5 percent, compared to 7.4 percent in the same period last year. The decline was primarily driven by higher amortization and lower capitalization, although this was partly offset by reduced selling and administrative expenses, reflecting the effect from our continued cost-saving initiatives. Operating cash flow after continuous investments improved by SEK 529 million, reaching SEK -361 million in the first quarter. This improvement was primarily driven by improved working capital management. Investor update On June 10, we held an Investor Update with the purpose of providing an update of our progress across several key projects as well as presenting the strong fundamentals of the radiation therapy industry. We reiterated the roadmap to achieve our mid-term financial objectives. This includes restoring the gross margin to pre-pandemic levels and reaching an EBIT margin of at least 14 percent. Key drivers are growing volumes, enhanced pricing supported by new product launches, an improved product mix, and accelerated expansion in mature markets. As part of our commitment to operational excellence, we also presented the result of a proactive order review aimed at increasing the quality of the backlog to improve profitability and predictability. Commercial milestones During the quarter, we delivered several important commercial wins with Elekta Evo and our software suite Elekta ONE. For example, we concluded a comprehensive deal including some of our most advanced solutions to the University of Texas Southwestern. Leksell Gamma Knife received FDA 510(k) clearance for treating a certain type of epilepsy, which is an important step towards expanding the scope of radiosurgery. We have also noted that the ERECT trial, demonstrating Elekta Unity’s capability to treat prostate cancer while preserving erectile function, has gained significant attention. Outlook We expect net sales for Q2 to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, we expect sales in China to start to recover during the second half of 2025/26. Furthermore, we expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in Q2. We reiterate our full year 2025/26 outlook, where we expect net sales in constant currency to grow year-over-year. I would like to end my CEO comment by welcoming Jakob Just-Bomholt as Elekta’s new CEO. Jakob is a highly experienced international executive with a successful career and CEO positions in various global industries, including the medtech sector. Jakob will assume his new role as CEO on September 1. Jonas Bolander President and CEO “Cash flow after continuous investments improved YoY by SEK 529 M “ SEK 529 M ===== SIDA 3 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 3 Financial highlights Net sales • 3 percent increase in constant exchange rates – driven by strong performance in Europe • China and U.S. sales continued to decline • The book-to-bill ratio was 1.05 (1.10) in the first quarter and rolling 12 months ended at 1.09 Based on constant exchange rates, Elekta’s net sales increased by 3 percent in the first quarter. The development was mainly driven by strong performance in Europe while China and U.S. sales continued to decline. Reported net sales decreased by 5 percent amounting to SEK 3,646 M (3,825). Sales in EMEA increased by 15 percent in constant exchange rates compared to last year. The development was mainly driven by continued strong momentum in Europe supported by new product launches. APAC sales declined year-over-year by 4 percent in constant exchange rates mainly due to lower volumes in China and India. Chinese sales were negatively impacted by last year’s weak order intake. Americas’ sales declined by 4 percent in constant exchange rates compared to last year when the region grew by 16 percent. The stable development in Latin America was fully offset by lower sales in North America where U.S. volumes declined mainly as a result of customers awaiting the Elekta Evo clearance. Solutions and Service increased sales by 1 percent and 4 percent respectively in constant exchange rates supported by software growth. Book-to-bill development The book-to-bill ratio was 1.05 (1.10) in the first quarter and the twelve-month rolling figure ended at 1.09. Gross order intake in the first quarter amounted to SEK 3,838 M (4,192), a decrease of 8 percent in SEK and 1 percent based on constant exchange rates. For more information about the book-to-bill ratio, see page 30. Sales per region Sales per product type 1 Based on constant exchange rates. 2 Compared to last fiscal year May 2024 – Apr 2025 based on constant exchange rates. SEK M 2025/26 2024/25 Δ1 Δ RTM 2024/25 Δ2 Δ Americas 1,071 1,241 -4% -14% 5,013 5,183 2% -3% EMEA 1,443 1,314 15% 10% 6,709 6,580 1% 2% APAC 1,132 1,270 -4% -11% 6,116 6,253 2% -2% Group 3,646 3,825 3% -5% 17,838 18,016 2% -1% Q1 12 months SEK M 2025/26 2024/25 Δ1 Δ RTM 2024/25 Δ2 Δ Solutions 1,805 1,915 1% -6% 10,121 10,232 1% -1% Service 1,842 1,909 4% -4% 7,717 7,784 2% -1% Group 3,646 3,825 3% -5% 17,838 18,016 2% -1% Q1 12 months ===== SIDA 4 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 4 FINANCIAL HIGHLIGHTS Earnings • Lower adjusted gross margin due to changes in FX of 100 bps and tariff costs of 90 bps • Higher amortization and lower capitalization partly offset by reduced selling and admin expenses • Significantly higher earnings per share compared to last year Gross income development In the first quarter, the adjusted gross income was SEK 1,350 M (1,445), representing an adjusted gross margin of 37.0 percent (37.8). The decline compared to last year was driven by a negative impact from changes in foreign exchange rates of 100 basis points and tariff costs of 90 basis points corresponding to a total amount of SEK 176 M. The negative impact was partly offset by price improvements. Reported gross income amounted to SEK 1,342 M (1,417), representing a margin of 36.8 percent (37.0). EBIT development Adjusted EBIT came in at SEK 235 M (283), representing a margin of 6.5 percent (7.4). The lower adjusted EBIT margin is derived mainly from the gross margin and increased expenses from net R&D. The negative effect was partly offset by lower selling and administrative expenses reflecting the positive effect from cost-saving initiatives. Reported EBIT amounted to SEK 219 M (174), representing a margin of 6.0 percent (4.5). Items affecting comparability (IAC) in the first quarter consisted of personnel-related costs amounting to SEK 16 M (109), whereof SEK 8 M (28) impacted the gross margin. Operating expenses, excluding IAC and based on constant exchange rates, increased by 4 percent during the first quarter. The increase compared to last year was driven by net R&D due to higher amortization of intangible assets following recent product launches and a lower capitalization level. It was partly offset by lower R&D investments as well as reductions in selling and administrative expenses, declining 4 percent and 3 percent respectively. This reflects Elekta’s continued commitment to improve cost efficiency and enhance productivity. Net income development Net financial items were in line with last year amounting to SEK -83 M (-83). Taxes amounted to SEK -30 M (-20), representing a tax rate of 22 percent (22). Net income amounted to SEK 106 M (71) and earnings per share to SEK 0.28 (0.18) before and after dilution. SEK M 2025/26 2024/25 Δ RTM 2024/25 Δ Net sales 3,646 3,825 -5% 17,838 18,016 -1% Net sales in constant currency 3% 2% Adjusted gross income 1,350 1,445 -7% 6,715 6,810 -1% Adjusted gross margin 37.0% 37.8% -0,8 ppts 37.6% 37.8% -0,2 ppts Adjusted EBIT 235 283 -17% 2,049 2,097 -2% Adjusted EBIT-margin 6.5% 7.4% -0,9 ppts 11.5% 11.6% -0,2 ppts EBIT 219 174 26% 935 890 5% EBIT-margin 6.0% 4.5% 1,5 ppts 5.2% 4.9% 0,3 ppts Net income 106 71 50% 276 240 15% Earnings per share 0.28 0.18 52% 0.71 0.62 15% Q1 12 months ===== SIDA 5 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 5 FINANCIAL HIGHLIGHTS Earnings Items affecting comparability Items affecting comparability mainly relates to personnel costs and reflect Elekta’s continued commitment to improve cost efficiency and enhance productivity. Employees The average number of employees on July 31, 2025, was 4,485 (4,566). Shares Total number of registered shares on July 31, 2025, was 383,568,409, of which 14,980,769 were A-shares and 368,587,640 B-shares. On July 31, 2025, 1,485,289 shares were treasury shares held by Elekta. Earnings per share was SEK 0.28 (0.18) before and after dilution. ===== SIDA 6 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 6 Cash flow and financial position • Improved cash flow after continuous investments by SEK 529 M year-over-year • Working capital as a percentage of net sales (rolling twelve months) improved to -7 percent (-5) • Rolling twelve months cash conversion at 92 percent Cash flow Cash flow after continuous investments amounted to SEK -361 M (-891), an improvement by SEK 529 M. The first quarter is seasonally the weakest cash flow quarter during the year. The strong year-over-year improvement was driven by a more favorable development of working capital. Lower investments contributed positively as well. Net working capital as a percentage of net sales (rolling twelve months) improved to -7 percent (-5). Investments in intangible assets amounted to SEK 246 M (336) and were mainly related to R&D investments in new product solutions and software. Investments in tangible assets decreased to SEK 29 M (61). Cash conversion in the first quarter was -16 percent (-95). Cash flow (extract) Financial position Cash and cash equivalents and short-term investments amounted to SEK 2,760 M (2,364). The increase compared to last year was driven by higher earnings and improved working capital. Interest-bearing liabilities, excluding lease liabilities, amounted to SEK 6,623 M (6,490). Net debt decreased to SEK 3,863 M (4,126). Net debt in relation to EBITDA was 1.17 (1.37). The average maturity of interest-bearing liabilities was 3.1 years. Net debt 1 EBITDA 12 months rolling SEK M 2025/26 2024/25 RTM 2024/25 EBITDA 532 522 3,293 3,283 Change in w orking capital -286 -933 444 -203 Financial net -83 -83 -399 -400 Paid tax -128 -60 -379 -311 Other -122 61 74 258 Cash flow from operating activities -86 -493 3,033 2,626 Continuous investments -275 -397 -1,447 -1,570 Cash flow after continuous investments -361 -891 1,586 1,056 Operational cash conversion -16% -95% 92% 80% Q1 12 months Jul 31 Jul 31 Apr 30 SEK M 2025 2024 2025 Long-term interest-bearing liabilities 5,708 4,811 6,195 Short-term interest-bearing liabilities 868 1,679 178 Derivatives, net 47 - 48 -2,760 -2,364 -2,955 Net debt 3,863 4,126 3,465 Long-term lease liabilities 926 1,052 961 Short-term lease liabilities 237 200 233 5,027 5,379 4,658 Net debt/EBITDA ratio 1 1.17 1.37 1.06 Cash and cash equivalents and short-term investments Net debt including lease liabilities ===== SIDA 7 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 7 Other information Risk and uncertainties Elekta’s presence in many geographical markets exposes the Group to political and economic risks on a global scale and/or in individual countries. For more details, please see the Annual Report 2024/25, page 25. Forward looking statements This is information such that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the below mentioned contact persons at 07:30 CEST on August 28, 2025. This report includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar matters. These forward- looking statements are based on current expectations about future events. Although the expectations described in these statements are assumed to be reasonable, there is no guarantee that such forward-looking statements will materialize or are accurate. Since these statements involve assumptions and estimates that are subject to risks and uncertainties, results could differ materially from those set out in the statement. Some of these risks and uncertainties are described further in the section “Risk and uncertainties”. Elekta undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or stock exchange regulations. Parent company The financial net decreased mainly due to lower dividends from subsidiaries and a negative impact from exchange rate differences. SEK 500 M of interest-bearing liabilities have been reclassified to current liabilities and certificates of SEK 199 M have been issued. Significant events Elekta to enhance cancer treatment in Croatia through strategic acquisition Elekta announced the acquisition of assets from its distributor in Croatia, a strategic move that will strengthen Elekta’s market position and enhance cancer treatment capabilities in the region. Elekta appoints Jakob Just-Bomholt as new President and CEO On June 9, Elekta announced the appointment by the Board of Directors of Jakob Just-Bomholt as its new President and Chief Executive Officer, effective September 1, 2025. Elekta leaders presented retrospective and future developments to investor community Elekta hosted its Investor Update at the company’s global headquarters in Stockholm, where key members of the management team – including President and CEO Jonas Bolander and CFO Tobias Hägglöv –presented Elekta’s innovative portfolio, market development, and future growth prospects. As part of its commitment to operational excellence, Elekta shared the results of a proactive order review aimed to improve the quality of the backlog resulting in improved profitability and predictability. The review resulted in a cancellation valued at SEK 4.9 billion, including orders to be cancelled after year-end FY24/25. Elekta receives U.S. FDA 510(k) clearance for its Gamma Knife radiosurgery system to treat patients with refractory, drug-resistant mesial temporal lobe epilepsy Elekta announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to include refractory, intractable mesial temporal lobe epilepsy (MTLE) in adults among its indications for use with the company’s Leksell Gamma Knife radiosurgery system. Intractable epilepsy, also known as drug-resistant epilepsy, is a form of the disease in which a person’s seizures cannot be controlled with medication. Gamma Knife surgery treats refractory, drug-resistant MTLE by precisely focusing 192 beams of gamma radiation to target and disrupt the exact region of the brain responsible for epileptic seizures, potentially reducing frequency or eliminating them without opening the skull. Significant events after the quarter No significant events after the quarter. ===== SIDA 8 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 8 Shareholder information Conference call Q1 Elekta will host a web conference at 10:00-11:00 CEST on August 28 with President and CEO Jonas Bolander, and CFO Tobias Hägglöv. To take part of the presentation please dial the numbers or watch via the web link below. Sweden: +46 (0) 8 5051 0031 UK: +44 (0) 207 107 06 13 US: +1 (1) 631 570 56 13 For further information, please contact: Tobias Hägglöv CFO +46 76 107 4799 tobias.hagglov@elekta.com Peter Nyquist VP, Head of Investor Relations +46 70 575 2906 peter.nyquist@elekta.com Financial calendar Annual General Meeting 2025 Sep 4, 2025 Interim report, Q2, May-Oct 2025/26 Nov 26, 2025 Interim report, Q3, May-Jan 2025/26 Mar 5, 2026 Interim report, Q4, May-Apr 2025/26 May 28, 2026 Web link > ===== SIDA 9 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 9 Stockholm Aug 28, 2025 Jonas Bolander President and CEO This report has not been reviewed by the Company’s auditors. ===== SIDA 10 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 10 Consolidated income statement – condensed SEK M Note 2025/26 2024/25 RTM 2024/25 Net sales 2 3,646 3,825 17,838 18,016 Cost of products sold -2,305 -2,408 -11,167 -11,270 Gross income 1,342 1,417 6,671 6,746 Selling expenses -377 -425 -1,602 -1,650 Administrative expenses -321 -379 -1,354 -1,412 R&D expenses -438 -436 -2,678 -2,676 Other operating income and expenses -10 -12 -106 -108 Exchange rate differences 23 9 4 -9 Operating income (EBIT) 219 174 935 890 Financial items, net -83 -83 -399 -400 Income after financial items 136 91 536 490 Income tax -30 -20 -260 -250 Net income for the period 3 106 71 276 240 Net income for the period attributable to: Parent Company shareholders 107 70 273 237 Non-controlling interests 0 0 3 4 Average number of shares Before dilution, millions 382 382 382 382 After dilution, millions 382 382 382 382 Earnings per share Before dilution, SEK 0.28 0.18 0.71 0.62 After dilution, SEK 0.28 0.18 0.71 0.62 12 monthsQ1 ===== SIDA 11 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 11 Consolidated statement of comprehensive income SEK M 2025/26 2024/25 RTM 2024/25 Net income for the period 106 71 276 240 Other comprehensive income: Items that w ill not be reclassified to the income statement: Remeasurements of defined benefit pension plans 0 - 1 1 Tax 0 - -3 -3 Total items that will not be reclassified to the income statement 0 - -2 -2 Items that subsequently may be reclassified to the income statement: Revaluation of cash flow hedges -20 29 45 94 Translation differences from foreign operations 192 -168 -1,025 -1,385 Tax 4 -6 -9 -19 Total items that subsequently may be reclassified to the income statement 176 -145 -989 -1,310 Other comprehensive income for the period 176 -145 -991 -1,312 Total comprehensive income for the period 282 -74 -715 -1,072 Comprehensive income attributable to: Parent Company shareholders 282 -74 -715 -1,072 Non-controlling interests 1 0 0 0 12 monthsQ1 ===== SIDA 12 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 12 Consolidated balance sheet statement – condensed Apr 30 SEK M Note 2025 2024 2025 Non-current assets Intangible assets 12,111 13,343 11,917 Right-of-use assets 977 1,083 1,006 Tangible assets 884 1,063 901 Financial assets 826 1,021 895 Deferred tax assets 910 865 841 Total non-current assets 15,708 17,376 15,560 Current assets Inventories 3,029 3,524 2,756 Accounts receivable 3,572 3,922 3,625 Accrued income 2,123 2,092 2,261 Other current receivables 1,959 2,138 1,820 Cash and cash equivalents 2,760 2,364 2,955 Total current assets 13,443 14,040 13,417 Total assets 29,151 31,416 28,977 Equity attributable to Parent Company shareholders 9,086 10,703 8,803 Non-controlling interests 46 5 45 Total equity 9,132 10,708 8,848 Non-current liabilities Interest-bearing liabilities 4 5,708 4,811 6,195 Lease liabilities 926 1,052 961 Other non-current liabilities 633 682 625 Total non-current liabilities 7,268 6,545 7,781 Current liabilities Interest-bearing liabilities 4 868 1,679 178 Lease liabilities 237 200 233 Accounts payable 1,643 1,571 1,837 Advances from customers 4,222 4,841 4,067 Prepaid income 2,737 2,913 2,831 Accrued expenses 2,067 1,902 2,245 Other current liabilities 978 1,057 957 Total current liabilities 12,751 14,163 12,348 Total equity and liabilities 29,151 31,416 28,977 Jul 31 ===== SIDA 13 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 13 Changes in consolidated equity – condensed Apr 30 SEK M 2025/26 2024/25 2024/25 Attributable to Parent Company shareholders Opening balance 8,803 10,774 10,774 Comprehensive income for the period 282 -74 -1,072 Incentive programs 2 4 18 Dividend - - -917 Total 9,086 10,703 8,803 Attributable to non-controlling interests Opening balance 45 5 5 Comprehensive income for the period 1 0 0 Acquisition of non-controlling interest - - 40 Total 46 5 45 Closing balance 9,132 10,708 8,848 Jul 31 ===== SIDA 14 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 14 Consolidated cash flow statement - condensed SEK M 2025/26 2024/25 RTM 2024/25 Income after financial items 136 91 536 490 Amortization and depreciation 313 317 1,295 1,299 Impairment - 31 1,094 1,094 Interest net 65 77 370 382 Other non-cash items -142 36 54 263 Interest received and paid -46 -52 -382 -388 Income taxes paid -128 -60 -379 -311 Operating cash flow 199 439 2,589 2,829 Change in inventories -253 -279 352 325 Change in operating receivables 423 -369 136 -657 Change in operating liabilities -456 -284 -44 128 Change in working capital -286 -933 444 -203 Cash flow from operating activities -86 -493 3,033 2,626 Investments in intangible assets -246 -336 -1,280 -1,370 Investments in tangible assets -29 -61 -167 -200 Continuous investments -275 -397 -1,447 -1,570 Cash flow after continuous investments -361 -891 1,586 1,056 Business combinations, dividends and investments associated companies 1 -12 -89 -102 Cash flow after investments -361 -903 1,496 953 Dividends - - -917 -917 Cash flow from other financing activities 126 504 -68 310 Cash flow for the period -235 -399 511 347 Change in cash and cash equivalents during the period Cash and cash equivalents at the beginning of the period 2,955 2,779 2,364 2,779 Cash flow for the period -235 -399 511 347 Exchange rate differences 39 -17 -115 -170 Cash and cash equivalents at the end of the period 2,760 2,364 2,760 2,955 12 monthsQ1 ===== SIDA 15 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 15 Parent company Income statement and statement of comprehensive income - condensed SEK M 2025/26 2024/25 Operating income and expenses -94 -108 Financial net -22 12 Income after financial items -116 -96 Tax 24 25 Net income for the period -92 -71 Statement of comprehensive income Net income for the period -92 -71 Total comprehensive income -92 -71 Balance sheet - condensed Jul 31 Apr 30 SEK M 2025 2025 Non-current assets Intangible assets 12 14 Shares in subsidiaries 4,531 4,530 Receivables from subsidaries 1,676 1,676 Other financial assets 35 36 Deferred tax assets 56 33 Total non-current assets 6,310 6,289 Current assets Receivables from subsidaries 3,431 3,811 Other current receivables 105 76 Cash and cash equivalents 1,066 1,360 Total current assets 4,602 5,247 Total assets 10,912 11,536 Shareholders' equity 1,594 1,685 Non-current liabilities Interest-bearing liabilities 5,761 6,248 Provisions 13 13 Total non-current liabilities 5,774 6,261 Current liabilities Interest-bearing liabilities 699 - Liabilities to Group companies 2,724 3,462 Short-term provisions 7 9 Other current liabilities 114 119 Total current liabilities 3,544 3,590 Total shareholders' equity and liabilities 10,912 11,536 Q1 ===== SIDA 16 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 16 Key figures and data per share 1 Attributable to Parent Company shareholders. 1 Number of registered shares at closing excluding treasury shares (1,485,289 per July 31, 2025). Key figures 2020/21 2021/22 2022/23 2023/24 2024/25 2024/25 2025/26 Gross order intake, SEK M 17,411 18,364 20,143 19,697 19,718 4,192 3,838 Net sales, SEK M 13,763 14,548 16,869 18,119 18,016 3,825 3,646 Gross margin, % 40.8 37.4 37.6 37.4 37.4 37.0 36.8 Adjusted gross margin, % 40.8 37.4 38.1 37.5 37.8 37.8 37.0 Operating income (EBIT), SEK M 1,906 1,643 1,431 2,039 890 174 219 Operating margin, % 13.9 11.3 8.5 11.3 4.9 4.5 6.0 Adjusted EBIT, SEK M 1,906 1,643 1,743 2,145 2,097 283 235 Adjusted EBIT margin, % 13.9 11.3 10.3 11.8 11.6 7.4 6.5 Shareholders' equity, SEK M 1 8,197 8,913 9,729 10,774 8,803 10,703 9,086 Return on shareholders' equity, % 16 14 10 13 2 11 3 Net debt, SEK M 774 1,532 2,442 3,150 3,465 4,126 3,863 Operational cash conversion, % 82 69 76 77 80 -95 -16 Average number of employees 4,194 4,631 4,587 4,607 4,536 4,566 4,485 Full-year May - Jul Data per share 2020/21 2021/22 2022/23 2023/24 2024/25 2024/25 2025/26 Earnings per share before dilution, SEK 3.28 3.02 2.47 3.41 0.62 0.18 0.28 after dilution, SEK 3.28 3.02 2.47 3.41 0.62 0.18 0.28 Adjusted earnings per share before dilution, SEK 3.28 3.02 3.11 3.62 3.08 0.41 0.31 after dilution, SEK 3.28 3.02 3.10 3.62 3.08 0.41 0.31 Cash flow per share before dilution, SEK 5.05 0.55 0.91 1.41 2.50 -2.36 -0.94 after dilution, SEK 5.05 0.55 0.91 1.41 2.50 -2.36 -0.94 Shareholders' equity per share before dilution, SEK 21.45 23.33 25.46 28.20 23.04 28.01 23.78 after dilution, SEK 21.45 23.33 25.44 28.20 23.04 28.01 23.78 Average number of shares before dilution, thousands 382,083 382,083 382,083 382,083 382,083 382,083 382,083 after dilution, thousands 382,083 382,083 382,367 382,086 382,139 382,083 382,135 Number of shares at closing 1 before dilution, thousands 382,083 382,083 382,083 382,083 382,083 382,083 382,083 after dilution, thousands 382,083 382,083 382,575 382,086 382,135 382,083 382,135 Full-year May - Jul ===== SIDA 17 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 17 Note 1 – Accounting principles This interim report is prepared, with regards to the Group, according to IAS 34 and the Swedish Annual Accounts Act and, with regards to the Parent Company, according to the Swedish Annual Accounts Act and RFR 2. The accounting principles applied are consistent with those presented in Note 1 of the Annual Report 2024/25. New or revised standards and interpretations, not yet applied, are not considered to have a material impact on the Elekta Group´s financial statements. All figures are stated in SEK M and, accordingly, rounding differences can occur. Comparisons refer to the corresponding period for the prior year, unless otherwise stated. Definitions and Alternative performance measures can be found on pages 102-105 in the Annual Report 2024/25. Related party transactions Related party transactions are described in note 37 in the Annual Report for 2024/25. Exchange rates For Group companies with a functional currency other than Swedish kronor, order intake and income statements are translated at average exchange rates for the reporting period, while balance sheets are translated at closing exchange rates. 1 July 31, 2025, vs July 31, 2024. Data per quarter 2025/26 SEK M Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Gross order intake 3,839 4,989 4,433 6,436 4,192 4,317 5,418 5,792 3,838 Net sales 3,828 4,732 4,537 5,023 3,825 4,341 4,695 5,156 3,646 Operating income (EBIT) 412 525 485 617 174 388 525 -197 219 Cash flow from operating activities -551 623 1,072 1,317 -493 456 1,095 1,568 -86 2023/24 2024/25 R&D expenditure SEK M 2025/26 2024/25 RTM 2024/25 R&D expenditure, gross 497 604 2,110 2,217 Capitalization -228 -326 -1,109 -1,207 Amortization 168 157 675 663 Impairment - - 1,002 1,002 R&D expenditure, net 438 436 2,678 2,676 Q1 12 months Country Currency Apr 30 2025 2024 Δ1 2025 2024 2025 Δ1 China 1 CNY 1.335 1.467 -9% 1.358 1.488 1.328 -9% Euroland 1 EUR 11.038 11.491 -4% 11.171 11.650 10.977 -4% Great Britain 1 GBP 12.938 13.540 -4% 12.962 13.824 12.924 -6% Japan 1 JPY 0.066 0.068 -2% 0.066 0.071 0.068 -7% United States 1 USD 9.602 10.635 -10% 9.769 10.762 9.651 -9% Closing rate May - Jul Average rate Jul 31 ===== SIDA 18 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 18 Note 2 – Net sales by product type In general, net sales from Solutions is taken at a point in time, net sales from Service is taken over time. Q1 2025/26 SEK M Americas EMEA APAC Group total Solutions 400 711 694 1,805 Service 671 733 438 1,842 Total 1,071 1,443 1,132 3,646 Q1 2024/25 SEK M Americas EMEA APAC Group total Solutions 475 623 817 1,915 Service 766 691 453 1,909 Total 1,241 1,314 1,270 3,825 Rolling twelve months SEK M Americas EMEA APAC Group total Solutions 2,106 3,781 4,234 10,121 Service 2,907 2,928 1,882 7,717 Total 5,013 6,709 6,116 17,838 Full year 2024/25 SEK M Americas EMEA APAC Group total Solutions 2,181 3,694 4,358 10,232 Service 3,002 2,886 1,896 7,784 Total 5,183 6,580 6,253 18,016 ===== SIDA 19 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 19 Note 3 – Segment reporting Elekta applies geographical segmentation. Net sales and contribution margin for the respective regions are reported to Elekta’s CFO and CEO (chief operating decision makers). The regions’ expenses are directly attributable to the respective regions’ reported figures including cost of products sold. Global costs for R&D, marketing, management of product supply centers and Parent Company are not allocated per region. Currency exposure is concentrated to product supply centers. The majority of exchange differences in operations are reported in global costs. Elekta’s operations are characterized by significant quarterly variations in volumes and product mix, which have a direct impact on net sales and profits. This is accentuated when the operation is split into segments, as is the impact of currency fluctuations between the years. In general, revenue from Solutions is recognized at a point in time and revenue from Service is recognized over time. 1 Items affecting comparability include mainly personnel costs and impairments of assets attributable to the Cost-reduction Initiative and the R&D impairment cost Q1 2025/26 SEK M Americas EMEA APAC Other / Group-wide Group total % of net sales Net sales 1,071 1,443 1,132 - 3,646 Operating expenses -697 -908 -731 - -2,335 64% Contribution margin 374 536 401 - 1,311 36% Contribution margin, % 35% 37% 35% Global costs - - - -1,076 -1,076 30% Adjusted EBIT 374 536 401 -1,076 235 6% Items affecting comparability1 -6 - - -10 -16 Operating income (EBIT) 368 536 401 -1,086 219 6% Net financial items - 404 - -486 -83 Income after financial items 368 940 401 -1,572 136 Income tax - - - -30 -30 Net income for the period 368 940 401 -1,602 106 Q1 2024/25 SEK M Americas EMEA APAC Other / Group-wide Group total % of net sales Net sales 1,241 1,314 1,270 - 3,825 Operating expenses -743 -890 -825 - -2,458 64% Contribution margin 498 424 445 - 1,367 36% Contribution margin, % 40% 32% 35% Global costs - - - -1,084 -1,084 28% Adjusted EBIT 498 424 445 -1,084 283 7% Items affecting comparability1 -7 -3 -7 -92 -109 Operating income (EBIT) 491 420 438 -1,176 174 5% Net financial items - - - -83 -83 Income after financial items 491 420 438 -1,259 91 Income tax - - - -20 -20 Net income for the period 491 420 438 -1,279 71 ===== SIDA 20 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 20 1 Items affecting comparability include mainly personnel costs and impairments of assets attributable to the Cost-reduction Initiative and the R&D impairment cost Rolling twelve months SEK M Americas EMEA APAC Other / Group-wide Group total % of net sales Net sales 5,013 6,709 6,116 - 17,838 Operating expenses -3,170 -4,264 -3,926 - -11,359 64% Contribution margin 1,843 2,445 2,190 - 6,478 36% Contribution margin, % 37% 36% 36% Global costs - - - -4,429 -4,429 25% Adjusted EBIT 1,843 2,445 2,190 -4,429 2,049 11% Items affecting comparability1 -21 -9 -2 -1,083 -1,114 Operating income (EBIT) 1,822 2,436 2,188 -5,512 935 5% Net financial items - 404 - -803 -399 Income after financial items 1,822 2,840 2,188 -6,315 536 Income tax - - - -260 -260 Net income for the period 1,822 2,840 2,188 -6,574 276 Full year 2024/25 SEK M Americas EMEA APAC Other / Group-wide Group total % of net sales Net sales 5,183 6,580 6,253 - 18,016 Operating expenses -3,216 -4,247 -4,020 - -11,482 64% Contribution margin 1,967 2,333 2,233 - 6,534 36% Contribution margin, % 38% 35% 36% Global costs - - - -4,437 -4,437 25% Adjusted EBIT 1,967 2,333 2,233 -4,436 2,097 12% Items affecting comparability1 -21 -12 -9 -1,164 -1,207 Operating income (EBIT) 1,946 2,321 2,224 -5,601 890 5% Net financial items - - - -400 -400 Income after financial items 1,946 2,321 2,224 -6,001 490 Income tax - - - -250 -250 Net income for the period 1,946 2,321 2,224 -6,251 240 ===== SIDA 21 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 21 Note 4 – Financial instruments The table below shows the fair value of the Group’s financial instruments, for which fair value is different than carrying value. The fair value of all other financial instruments is assumed to correspond to the carrying value. The Group’s financial assets and financial liabilities, which have been measured at fair value, have been categorized in the fair value hierarchy. The different levels are defined as follows: Level 1: Quoted prices on an active market for identical assets or liabilities Level 2: Other observable data than quoted prices included in Level 1, either directly (that is, price quotations) or Indirectly (that is, obtained from price quotations) Level 3: Data not based on observable market data SEK M Carrying amount Fair value Carrying amount Fair value Carrying amount Fair value Long-term interest-bearing liabilities 5,708 6,009 4,811 5,515 6,195 6,505 Short-term interest-bearing liabilities 868 877 1,679 1,725 178 178 Apr 30, 2025Jul 31, 2025 Jul 31, 2024 Financial instruments measured at fair value SEK M Level Jul 31, 2025 Jul 31, 2024 Apr 30, 2025 FINANCIAL ASSETS Financial assets measured at fair value through income statement: Derivative financial instruments – non-hedge accounting 2 53 76 33 Derivatives used for hedging purposes: Derivative financial instruments – hedge accounting 2 142 120 174 Total financial assets measured at fair value 194 196 207 FINANCIAL LIABILITIES Financial liabilities at fair value through income statement: Derivative financial instruments – non-hedge accounting 2 91 35 79 Contingent considerations 3 78 77 75 Derivatives used for hedging purposes: Derivative financial instruments – hedge accounting 2 39 63 51 Total financial liabilities measured at fair value 208 175 205 ===== SIDA 22 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 22 The fair value of accounts receivables, other current and non-current receivables, cash and cash equivalents, accounts payable and other current and non-current liabilities is estimated to be equal to their carrying amount. Movements financial instruments level 3 SEK M Jul 31, 2025 Jul 31, 2024 Apr 30, 2025 Opening balance 75 76 76 Business combinations - - 48 Payments - - -43 Reported in net income for the period 1 0 1 Translation differences 2 1 -6 Closing balance 78 77 75 ===== SIDA 23 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 23 Alternative performance measures Alternative Performance Measures (APMs) are measures and key figures that Elekta’s management and other stakeholders use when managing and analysing Elekta’s business performance. These measures are not substitutes, but rather supplements to financial reporting measures prepared in accordance with IFRS. Key figures and other APMs used by Elekta are defined on ir.elekta.com/investors/financials. Definitions and additional information on APMs can also be found on pages 102-105 in the Annual Report 2024/25. Sales growth based on constant exchange rates per region Sales growth based on constant exchange are, to a large extent, reported in subsidiaries with other functional currencies than SEK, which is the group reporting currency. In order to present sales growth on a more comparable basis and to show the impact of currency fluctuations, sales growth based on constant exchange rates are presented. The schedules below present growth based on constant exchange rates reconciled to the total growth reported in accordance with IFRS. % SEK M % SEK M % SEK M % SEK M Q1 2025/26 vs. Q1 2024/25 Change based on constant exchange rates -4 -46 15 197 -4 -49 3 102 Currency effects -10 -124 -5 -67 -7 -89 -7 -281 Reported change -14 -170 10 129 -11 -138 -5 -178 Q1 2024/25 vs. Q1 2023/24 Change based on constant exchange rates 16 176 -12 -177 3 42 1 40 Currency effects -1 -6 0 -7 -2 -30 -1 -43 Reported change 16 170 -12 -184 1 11 0 -3 Aug - Jul 2025/26 vs. May - Apr 2024/25 Change based on constant exchange rates 2 121 1 67 2 105 2 293 Currency effects -6 -291 1 62 -4 -243 -3 -471 Reported change -3 -170 2 129 -2 -138 -1 -178 Aug - Jul 2024/25 vs. May - Apr 2023/24 Change based on constant exchange rates -2 -128 -4 -286 1 50 -2 -364 Currency effects 5 298 1 102 -1 -39 2 361 Reported change 3 170 -3 -184 0 11 0 -3 Americas EMEA APAC Group total ===== SIDA 24 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 24 Sales growth based on constant exchange rates per product Sales growth based on constant exchange are, to a large extent, reported in subsidiaries with other functional currencies than SEK, which is the group reporting currency. In order to present sales growth on a more comparable basis and to show the impact of currency fluctuations, sales growth based on constant exchange rates are presented. The schedules below present growth based on constant exchange rates reconciled to the total growth reported in accordance with IFRS. % SEK M % SEK M % SEK M Q1 2025/26 vs. Q1 2024/25 Change based on constant exchange rates 1 23 4 80 3 102 Currency effects -7 -133 -8 -147 -7 -281 Reported change -6 -111 -4 -67 -5 -178 Q1 2024/25 vs. Q1 2023/24 Change based on constant exchange rates -3 -60 5 101 1 41 Currency effects -1 -20 -1 -24 -1 -44 Reported change -4 -79 4 76 0 -3 Aug - Jul 2025/26 vs. May - Apr 2024/25 Change based on constant exchange rates 1 152 2 141 2 293 Currency effects -3 -263 -3 -208 -3 -471 Reported change -1 -111 -1 -67 -1 -178 Aug - Jul 2024/25 vs. May - Apr 2023/24 Change based on constant exchange rates -2 -210 -2 -153 -2 -363 Currency effects 1 131 3 229 2 360 Reported change -1 -79 1 76 0 -3 Solutions Service Total sales ===== SIDA 25 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 25 Change of expenses Management reviews the development of expenses excluding items affecting comparability in constant currencies. The schedule below illustrates the reported change in expenses for items affecting comparability and the remaining change split between change based on constant exchange rates and change due to currency movements. EBITDA EBITDA is used for the calculation of operational cash conversion and the net debt/EBITDA ratio. Return on shareholders’ equity Return on shareholders’ equity measures the return generated on shareholders’ capital invested in the company. % SEK M % SEK M % SEK M % SEK M Q1 2025/26 vs. Q1 2024/25 Change in items affecting comparability -1 -3 -10 -35 -9 -35 -6 -73 Change based on constant exchange rates -4 -16 -3 -10 17 68 4 43 Currency effects -7 -30 -4 -14 -8 -31 -6 -74 Reported change -12 -48 -17 -58 1 2 -9 -104 Q1 2024/25 vs. Q1 2023/24 Change in items affecting comparability 0 -1 10 30 10 38 6 68 Change based on constant exchange rates 0 -1 8 25 3 12 3 36 Currency effects -2 -7 3 9 0 0 0 2 Reported change -2 -9 21 65 13 50 9 106 Selling expenses Administrative expenses R&D expenses Change expenses SEK M Q1 2024/25 Q2 2024/25 Q3 2024/25 Q4 2024/25 Q1 2025/26 Operating income (EBIT) 174 388 525 -197 219 Amortization intangible assets: Capitalized development costs 159 165 179 172 172 Assets relating to other intangibles 39 40 45 41 34 Depreciation tangible assets 119 116 114 109 107 Impairment 31 -3 3 1,064 - EBITDA 522 706 866 1,189 532 SEK M Q1 2024/25 Q2 2024/25 Q3 2024/25 Q4 2024/25 Q1 2025/26 Net income (12 months rolling) 1,134 1,002 1,037 237 273 Average shareholders' equity excluding non-controlling interests (last five quarters) 10,460 10,502 10,585 10,297 9,959 Return on shareholders' equity 11% 10% 10% 2% 3% ===== SIDA 26 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 26 Operational cash conversion Cash flow is a focus area for management. The operational cash conversion shows the relation between cash flow from operating activities and EBITDA. Working capital In order to optimize cash generation, management focuses on working capital and reducing lead times between orders booked and cash received. SEK M Q1 2024/25 Q2 2024/25 Q3 2024/25 Q4 2024/25 Q1 2025/26 Cash flow from operating activities -493 456 1,095 1,568 -86 EBITDA 522 706 866 1,189 532 Operational cash conversion -95% 65% 126% 132% -16% Jul 31 Jul 31 Apr 30 SEK M 2025 2024 2025 Working capital assets Inventories 3,029 3,524 2,756 Accounts receivable 3,572 3,922 3,625 Accrued income 2,123 2,092 2,261 Other operating receivables 1,409 1,529 1,308 Sum working capital assets 10,133 11,067 9,950 Working capital liabilities Accounts payable 1,643 1,571 1,837 Advances from customers 4,222 4,841 4,067 Prepaid income 2,737 2,913 2,831 Accrued expenses 2,067 1,902 2,245 Short-term provisions 151 186 148 Other current liabilities 531 568 516 Sum working capital liabilities 11,350 11,981 11,644 Net working capital -1,217 -913 -1,694 % of rolling 12 months net sales -7% -5% -9% ===== SIDA 27 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 27 Net debt and net debt/EBITDA ratio Net debt is important for understanding the financial stability of the company. Net debt and net debt/EBITDA ratio are used by management to track the debt evolvement, the refinancing need and the leverage for the Group. Items affecting comparability by segment and nature of expense The costs are adjusted in order to track the underlying profitability of the Group’s products and services. The costs include mainly personnel costs and impairments of assets attributable to the Cost-reduction Initiative and the R&D impairment cost SEK M Jul 31, 2024 Oct 31, 2024 Jan 31, 2025 Apr 30, 2025 Jul 31, 2025 Long-term interest-bearing liabilities 4,811 6,307 6,291 6,195 5,708 Short-term interest-bearing liabilities 1,679 1,747 1,330 178 868 Derivatives, net - - 1 48 47 Cash and cash equivalents and short-term investments -2,364 -3,352 -3,583 -2,955 -2,760 Net debt 4,126 4,702 4,039 3,465 3,863 EBITDA (12 months rolling) 3,018 2,925 3,025 3,283 3,293 Net debt/EBITDA ratio 1.37 1.61 1.34 1.06 1.17 Q1 2025/26 SEK M Americas EMEA APAC Other / Group-wide Group total Items affecting comparability: Personnel related costs 6 - 0 10 16 Depreciation and impairment - - - - - Other costs - - 0 0 0 Total 6 - - 10 16 Q1 2024/25 SEK M Americas EMEA APAC Other / Group-wide Group total Items affecting comparability: Personnel related costs 7 3 7 52 69 Depreciation and impairment 0 - 0 31 31 Other costs 0 0 0 8 9 Total 7 3 7 92 109 12 months RTM SEK M Americas EMEA APAC Other / Group-wide Group total Items affecting comparability: Personnel related costs 20 9 2 45 77 Depreciation and impairment - - - 1,063 1,063 Other costs 0 0 0 -25 -25 Total 21 9 2 1,083 1,114 ===== SIDA 28 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 28 Gross margin & Adjusted gross margin Gross margin is used to track operational performance and efficiency and Adjusted gross margin is used to track the underlying operational performance, i.e. excluding items affecting comparability. EBITDA margin & Adjusted EBITDA margin Full year 2024/25 SEK M Americas EMEA APAC Other / Group-wide Group total Items affecting comparability: Personnel related costs 21 12 9 88 130 Depreciation and impairment - - - 1,094 1,094 Other costs 0 0 0 -17 -17 Total 21 12 9 1,165 1,207 SEK M 2025/26 2024/25 RTM 2024/25 Net sales 3,646 3,825 17,838 18,016 Cost of products sold -2,305 -2,408 -11,167 -11,270 Gross income 1,342 1,417 6,671 6,746 Items affecting comparability 8 28 44 64 Adjusted gross income 1,350 1,445 6,715 6,810 Gross margin (Gross income/ Net sales) 36.8% 37.0% 37.4% 37.4% 37.0% 37.8% 37.6% 37.8% Q1 12 months Adjusted gross margin (Adjusted gross income/ Net sales) SEK M 2025/26 2024/25 RTM 2024/25 EBITDA 532 522 3,293 3,283 Items affecting comparability 16 78 52 113 Adjusted EBITDA 548 600 3,345 3,396 - - Net Sales 3,646 3,825 17,838 18,016 EBITDA margin (EBITDA/Net sales) 14.6% 13.6% 18.5% 18.2% Adjusted EBITDA margin (Adjusted EBITDA/Net sales) 15.0% 15.7% 18.8% 18.8% Q1 12 months ===== SIDA 29 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 29 Adjusted EBIT by segment Adjusted EBIT is used to track the underlying operational performance, i.e. excluding items affecting comparability. Q1 2025/26 SEK M Americas EMEA APAC Other / Group-wide Group total Operating Income (EBIT) 368 536 401 -1,086 219 Items affecting comparability 6 - 0 10 16 Adjusted EBIT 374 536 401 -1,076 235 Q1 2024/25 SEK M Americas EMEA APAC Other / Group-wide Group total Operating Income (EBIT) 491 420 438 -1,176 174 Items affecting comparability 7 3 7 92 109 Adjusted EBIT 498 424 445 -1,084 283 12 Months rolling SEK M Americas EMEA APAC Other / Group-wide Group total Operating Income (EBIT) 1,822 2,436 2,188 -5,512 935 Items affecting comparability 21 9 2 1,083 1,114 Adjusted EBIT 1,843 2,445 2,190 -4,429 2,049 Full year 2024/25 SEK M Americas EMEA APAC Other / Group-wide Group total Operating Income (EBIT) 1,946 2,321 2,224 -5,601 890 Items affecting comparability 21 12 9 1,164 1,207 Adjusted EBIT 1,967 2,333 2,233 -4,437 2,097 ===== SIDA 30 ===== Interim report first quarter May–July 2025/26 ELEKTA Q1 2025/26 30 Adjusted earnings per share Adjusted earnings per share is used to track the underlying operational performance, i.e. excluding items affecting comparability. 1 Adjusted net income/average number of shares before dilution 2 Adjusted net income/average number of shares after dilution Adjusted R&D expenditure of net sales Adjusted R&D expenditure of net sales is used to track the amount spent on R&D in relation to net sales during the period, excluding items affecting comparability. Book-to-bill Book-to-bill is used to measure the company’s growth. A quota exceeding 1 shows that gross order intake is higher than the net sales. SEK M 2025/26 2024/25 RTM 2024/25 Net income for the period attributable to: Parent Company shareholders 107 70 273 237 Items affecting comparability 16 109 1,114 1,207 Tax on Items affecting comparability -4 -24 -245 -266 Adjusted net income 119 155 1,142 1,178 Average number of shares, before dilution 382 382 382 382 Average number of shares, after dilution 382 382 382 382 Adjusted earnings per share before dilution 1 0.31 0.41 2.99 3.08 Adjusted earnings per share after dilution 2 0.31 0.41 2.99 3.08 Q1 12 months SEK M 2025/26 2024/25 RTM 2024/25 R&D expenditure, net 438 436 2,678 2,676 R&D items affecting comparability -3 -38 -987 -1,023 R&D capitalization 228 326 1,109 1,207 R&D amortization -168 -157 -675 -663 Adjusted R&D Expenditure, gross 494 566 2,125 2,197 Net Sales 3,646 3,825 17,838 18,016 Adjusted R&D Expenditure of net sales 14% 15% 12% 12% 12 monthsQ1 SEK M 2025/26 2024/25 RTM 2024/25 Gross order intake 3,838 4,192 19,364 19,718 Net sales 3,646 3,825 17,838 18,016 Book-to-bill 1.05 1.10 1.09 1.09 Q1 12 months ===== SIDA 31 ===== Elekta AB Box 7593 SE – 103 93 Stockholm, Sweden T +46 8 587 254 00 F +46 8 587 255 00 elekta.com /elekta @elekta /company/elekta @elekta_ About Elekta Elekta is a global leader in radiotherapy solutions to fight cancer and neurological diseases. In fact, we are the only independent radiotherapy provider of scale. We have a broad offering of advanced solutions for delivering the most efficient radiotherapy treatments. Elekta’s offering allows clinicians to treat more patients with increased quality, both with value- creating innovations in solutions and AI-supported service based on a global network.